Each platform below represents a new category in medical photonics — engineered from first principles at Toronto University Hospital and protected by Canadian and international patents.
Five proprietary platforms, each targeting a distinct frontier in non-invasive diagnostics and therapy.
Mitochondrial oxygen mapping via quantum dot spectroscopy
Tumour microenvironment detection via BRET photonics
47-biomarker simultaneous detection in 0.4 seconds
Diagnose and heal tissue simultaneously with NIR pulses
Through-skull cortical blood-flow mapping, no MRI required
QuantaFlux is the world's first system to non-invasively map mitochondrial oxygen consumption at sub-cellular resolution through intact skin. Traditional methods required biopsies or invasive probes. Our quantum dot emitter arrays broadcast 12 precisely tuned wavelengths simultaneously, each tuned to a specific cytochrome absorption band within the mitochondrial electron transport chain.
The reflected spectral signatures are captured by a 2048-pixel CMOS spectrometer array and processed by our embedded QuantaCore AI chip in 0.8 seconds, producing a real-time metabolic activity map with 0.8 micron spatial resolution.
BLRI is built on a radical insight: every tumour microenvironment produces a unique bioluminescent resonance energy transfer (BRET) signature caused by oxidative stress metabolites and hypoxia-driven NADH fluorescence. For decades, detecting these signatures required injected contrast agents or ex-vivo cell cultures.
Our external BLRI sensor generates a coherent low-power excitation field that stimulates and captures these endogenous photonic emissions through skin and superficial tissue — identifying cancer recurrence, inflammatory cascades, and fibrotic changes up to 3 weeks before they appear on PET-CT imaging.
ChromaDerm replaces the blood draw. A single 0.4-second pass of our multi-spectral probe over the forearm returns a complete biochemical panel — 47 biomarkers simultaneously decoded by our ChromaNet deep-learning model trained on 2.4 million annotated patient spectra from Toronto University Hospital.
The system works by exploiting the unique near-infrared and mid-infrared absorption fingerprints of each target molecule in dermal capillary blood. Glucose, cortisol, haemoglobin A1c, fibrinogen, D-dimer, interleukin-6, and 41 more — all from a gentle, room-temperature light touch.
PhoTissue Wave Therapy is the world's first device that simultaneously diagnoses and treats tissue pathology using a single adaptive light source. During the diagnostic phase, low-coherence interferometry maps tissue damage extent, inflammation depth, and vascular disruption. In the same session, the device automatically switches to therapeutic mode, delivering precisely shaped photobiomodulation pulses that activate cytochrome c oxidase in mitochondria — accelerating cellular repair without drugs.
Clinical pilots at Toronto University Hospital's wound care unit showed a 67% reduction in chronic wound healing time compared to standard care, with simultaneous real-time healing-progress monitoring.
NeuroPulse Optical Mapping achieves what functional MRI offers — real-time cortical activity mapping — but without the machine, without the noise, and without the cost. Using a phased array of 256 photonic emitters arranged in a non-contact helmet, NPOM projects time-domain diffuse optical tomography pulses through the skull, measuring the haemodynamic response of neural circuits with 1mm² spatial resolution.
The system reconstructs a full 3D cortical perfusion map every 200 milliseconds, enabling bedside monitoring of stroke progression, seizure propagation, post-surgical neural recovery, and sedation depth — all without moving the patient to an MRI suite.
Schedule a live demonstration at our Toronto University Hospital lab or arrange a remote briefing with our science team.